Synthetic vaccines for Indiana and New Jersey type vesicular-stomatitis virus: surface glycoprotein gene cloning in recombinant vaccinia virus

Vaccine ◽  
1988 ◽  
Vol 6 (6) ◽  
pp. 541-541
Keyword(s):  
Vaccinia Virus ◽  
Gene Cloning ◽  
Vesicular Stomatitis Virus ◽  
Recombinant Vaccinia Virus ◽  
Surface Glycoprotein ◽  
Virus Surface ◽  
Recombinant Vaccinia ◽  
Synthetic Vaccines ◽  
Glycoprotein Gene ◽  
Vesicular Stomatitis

scholarly journals Preparation of Class Y Immunoglobulins that Neutralize the Marburg Virus

2021 ◽  
pp. 86-91
Author(s):  
O. A. Polezhaeva ◽  
A. V. Zybkina ◽  
A. V. Zaikovskaya ◽  
O. V. P’yankov ◽  
S. A. P’yankov ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Vesicular Stomatitis Virus ◽  
Neutralizing Antibodies ◽  
Recombinant Strain ◽  
Recombinant Vaccinia Virus ◽  
Marburg Virus ◽  
Surface Glycoprotein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Recombinant Vaccinia ◽  
Vesicular Stomatitis

The aim was to study the possibility of inducing Marburg-neutralizing chicken antibodies (MARV) using various immunogens.Materials and methods. Recombinant vaccinia virus expressing the surface glycoprotein (GP) transgene MARV of Musoke strain and pseudovirus particles exhibiting GP of three strains of MARV – Popp, Musoke and DRC2000 based on lentivirus and recombinant strain of vesicular stomatitis virus (VSV) were used as immunogens. Two groups of birds were involved in the study. Chickens were immunized 9 times: first time they were injected with the recombinant vaccinia virus, and then 8 times – with pseudovirus particles (based on lentivirus and a recombinant strain of the vesicular stomatitis virus). The accumulation of specific antibodies was evaluated by enzyme-linked immunosorbent assay (ELISA). We used recombinant VSV exhibiting GP MARV, and natural MARV strain Popp for the analysis of accumulation of neutralizing antibodies.Results and discussion. We have developed an effective immunization schedule for chickens with three recombinant constructs presenting GP MARV, which results in the induction of chicken IgY antibodies against Marburg virus with a titer in ELISA from 1:100 to 1:1 million. The obtained IgY neutralize MARV pseudoviruses (Popp, DRC2000, Musoke) at a dilution of 1/256 to 1/1024 and the natural MARV virus of the Popp strain at a dilution of 1/8. More stable results were demonstrated by immunization using Freund’s incomplete adjuvant. 

Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection

1988 ◽  
Vol 9 (2-3) ◽  
pp. 233-248 ◽  
Author(s):  
David D. Auperin ◽  
Joseph J. Esposito ◽  
James V. Lange ◽  
Sally P. Bauer ◽  
Janice Knight ◽  
...  
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Guinea Pigs ◽  
Recombinant Vaccinia Virus ◽  
Lassa Virus ◽  
Recombinant Vaccinia ◽  
Virus Glycoprotein ◽  
Glycoprotein Gene

scholarly journals Rearrangement of the Genes of Vesicular Stomatitis Virus Eliminates Clinical Disease in the Natural Host: New Strategy for Vaccine Development

2001 ◽  
Vol 75 (13) ◽  
pp. 6107-6114 ◽  
Author(s):  
E. Brian Flanagan ◽  
Joann M. Zamparo ◽  
L. Andrew Ball ◽  
Luis L. Rodriguez ◽  
Gail W. Wertz
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Gene Rearrangement ◽  
Vaccine Development ◽  
Natural Host ◽  
Surface Glycoprotein ◽  
Live Attenuated Vaccine ◽  
Glycoprotein Gene ◽  
New Strategy ◽  
Nucleocapsid Protein Gene ◽  
Vesicular Stomatitis

ABSTRACT Gene expression among the nonsegmented negative-strand RNA viruses is controlled by distance from the single transcriptional promoter, so the phenotypes of these viruses can be systematically manipulated by gene rearrangement. We examined the potential of gene rearrangement as a means to develop live attenuated vaccine candidates againstVesicular stomatitis virus (VSV) in domestic swine, a natural host for this virus. The results showed that moving the nucleocapsid protein gene away from the single transcriptional promoter attenuated and ultimately eliminated the potential of the virus to cause disease. Combining this change with relocation of the surface glycoprotein gene yielded a vaccine that protected against challenge with wild-type VSV. By incremental manipulation of viral properties, gene rearrangement provides a new approach to generating live attenuated vaccines against this class of virus.

scholarly journals Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.

1987 ◽  
Vol 7 (7) ◽  
pp. 2538-2544 ◽  
Author(s):  
T R Fuerst ◽  
P L Earl ◽  
B Moss
Keyword(s):  
Rna Polymerase ◽  
Vaccinia Virus ◽  
Target Gene ◽  
Target Genes ◽  
Expression System ◽  
Recombinant Vaccinia Virus ◽  
T7 Rna Polymerase ◽  
Bacteriophage T7 ◽  
Virus Surface ◽  
Recombinant Vaccinia

A novel expression system based on coinfection of cells with two recombinant vaccinia viruses has been developed. One recombinant vaccinia virus contained the bacteriophage T7 RNA polymerase gene under control of a vaccinia virus promoter. The second recombinant vaccinia virus contained a target gene of choice flanked by bacteriophage T7 promoter and termination sequences. Maximum expression of the target gene occurred when cells were infected with 10 PFU of each recombinant virus. Although T7 RNA polymerase synthesis began shortly after infection, the target gene was not expressed until late times and was largely inhibited when DNA replication was blocked. Target gene transcripts were analyzed by agarose gel electrophoresis and had the predicted size. With this system, Escherichia coli beta-galactosidase, hepatitis B virus surface antigen, and human immunodeficiency virus envelope proteins were made. In each case, the level of synthesis was greater than had previously been obtained with the more conventional recombinant vaccinia virus expression system.

Sign in / Sign up

Export Citation Format

Share Document